
Insights from 2024 SGO Annual Meeting
SGO 2024 Insights: "RUBY Part 1 & Part 2 Trial - Dostarlimab + Chemo for Primary Advanced/Recurrent Endometrial Cancer & PARPi Maintenance in Patients Receiving Dostarlimab + Chemo"
By
Insights from 2024 SGO Annual Meeting
FEATURING
Mansoor Raza Mirza
By
Insights from 2024 SGO Annual Meeting
FEATURING
Mansoor Raza Mirza
492 views
April 9, 2024
Chapters
Background and Key Results from RUBY Part 1
00:00
Advancements in RUBY Part 2
05:55
Safety and Adverse Events
09:40
Comments 0
Login to view comments.
Click here to Login
Videos